Is OnKure Therapeutics, Inc. profitable?

OnKure Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.7M over the trailing twelve months.

What is OnKure Therapeutics, Inc.'s earnings per share?

OnKure Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.

Where does OnKure Therapeutics, Inc.'s income statement data come from?

Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

OnKure Therapeutics, Inc. OKUR Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Net interest income	$3.43M+100%	$1.71M+5.5%	$1.62M—	——
Total interest income	$3.44M+70.9%	$2.01M+24.0%	$1.62M—	——
Research and development	$48.26M+10.2%	$43.8M—	——	$37.71M+33.9%
General and administrative	$14.69M+38.7%	$10.59M—	——	$16.14M+38.6%
Other operating expenses	$62.95M+15.7%	$54.39M—	——	$53.85M+35.2%
Total operating expenses	$62.95M+15.7%	$54.39M—	——	$53.85M+35.2%
Operating income	-$62.95M-15.7%	-$54.39M—	——	-$53.85M-35.2%
Net income	-$59.52M-13.0%	-$52.67M—	——	-$51.96M-30.6%
Diluted earnings per share	-$4.41—	——	-$113.23-5,266%	-$2.11+56.0%
Basic earnings per share	-$4.41—	——	-$113.23-5,266%	-$2.11+56.0%
Weighted-average shares, diluted	54M+1,129%	4.4M-92.5%	58.9M-39.8%	97.9M+48.4%
Weighted-average shares, basic	54M+1,129%	4.4M-92.5%	58.9M-39.8%	97.9M+48.4%
Interest Income (Expense), Operating	$3.43M+100%	$1.71M+5.5%	$1.62M—	——
Interest Income Operating	$3.44M+70.9%	$2.01M+24.0%	$1.62M—	——
EBIT	-$62.95M-15.7%	-$54.39M—	——	-$53.85M-35.2%
EBITDA	-$62.5M-15.9%	-$53.93M—	——	-$53.76M-35.2%
EBITDA	-$62.5M-15.9%	-$53.93M—	——	-$53.76M-35.2%
EBIT	-$62.95M-15.7%	-$54.39M—	——	-$53.85M-35.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is OnKure Therapeutics, Inc. profitable?: OnKure Therapeutics, Inc. is not currently profitable: it reported a net loss of $58.7M over the trailing twelve months.
What is OnKure Therapeutics, Inc.'s earnings per share?: OnKure Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-4.33.
Where does OnKure Therapeutics, Inc.'s income statement data come from?: Every line is extracted from OnKure Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.